Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,373 | 0,384 | 29.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Sensorion completes enrollment for second cohort in gene therapy trial | 3 | Investing.com | ||
Di | Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial | 198 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN),a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
01.07. | Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 275 | Business Wire | SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far Three-month results from a SENS-501 treated toddler in the first... ► Artikel lesen | |
13.05. | Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions | 350 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
06.05. | Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting | 309 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
25.04. | Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting | 519 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
18.04. | Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 12, 2025 | 460 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
SENSORION Aktie jetzt für 0€ handeln | |||||
16.04. | Sensorion to Host a Symposium during ISIET's International Conference on Inner Ear Therapies on April 26, 2025 | 362 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
02.04. | Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director | 358 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
31.03. | Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025 | 296 | Business Wire | Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET)
Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering... ► Artikel lesen | |
26.03. | Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences | 599 | Business Wire |
Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
14.03. | Sensorion reports FY results | 4 | Seeking Alpha | ||
14.03. | Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report | 16.157 | Business Wire | Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during... ► Artikel lesen | |
07.03. | Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity | 438 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
21.02. | Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501's Audiogene Phase 1/2 Clinical Trial | 370 | Business Wire | Committee recommends continuation of Audiogene after reviewing first cohort safety data Completion of Audiogene's second cohort enrollment on track for H1 2025
Regulatory News:
Sensorion... ► Artikel lesen | |
20.02. | Sensorion Announces Its Participation in Several Investor Conferences to be Held in March | 403 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
18.02. | Sensorion Announces Its Participation In Several Congresses To Be Held In March | 393 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
12.02. | Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting | 310 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders... ► Artikel lesen | |
27.12.24 | Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial | 591 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
18.12.24 | Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 517 | Business Wire | SENS-501 gene therapy product and surgical procedure are well tolerated by the first two treated patients and encouraging behavioural changes are observed in both toddlers Sensorion plans... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,25 | -0,26 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
EVOTEC | 7,400 | -0,54 % | Evotec, Gerresheimer, Hugo Boss, Puma, Renk Group, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
MEDIGENE | 0,119 | -1,24 % | Medigene bestellt neuen Vorstand - CEO Selwyn Ho geht | Die Medigene AG kündigt den Ausstieg des Vorstandsvorsitzenden Selwyn Ho zum 24. Juli 2025 an. Das Unternehmen betont, dass dieser Schritt nicht im Zusammenhang mit dem laufenden vorläufigen Insolvenzverfahren... ► Artikel lesen | |
CUREVAC | 4,646 | -0,68 % | CureVac dreht am Kursrad - jetzt lesen, was Analysten sagen!! | ||
MODERNA | 28,035 | -0,87 % | 3 Charts in 3x33 Sekunden - Heute mit Moderna, Silber und RWE | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
VALNEVA | 3,292 | +0,49 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.07.2025 / 16:05 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
AMGEN | 261,75 | -0,36 % | Dogs of the Dow: Why Amgen's (AMGN) Dividend Power Makes it a Standout Pick | ||
EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
NOVAVAX | 6,050 | -0,38 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
BIOFRONTERA | 2,800 | +1,45 % | PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG | DJ PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR... ► Artikel lesen | |
BIOGEN | 111,00 | +0,23 % | Biogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB), Friday announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has backed marketing authorization for ZURZUVAE... ► Artikel lesen | |
HEIDELBERG PHARMA | 4,420 | +2,08 % | EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Bezug von 90.000 Aktien aufgrund der Ausübung von 90.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2011 (Tranche 2; Ausgabe 2016) ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.07.2025 / 14:23... ► Artikel lesen | |
4SC | 0,610 | -1,61 % | XFRA VSC: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL4SC AG INH. O.N.... ► Artikel lesen | |
CRISPR THERAPEUTICS | 51,50 | 0,00 % | The 3 Things That Matter for CRISPR Therapeutics Now | ||
NANOREPRO | 1,475 | -2,32 % | NanoRepro: Gute Kombination | Als NanoRepro im Oktober 2008 an die Börse ging, war der Namenszusatz "Nano" mächtig angesagt. Immerhin starteten zwischen 2005 und 2026 auch die Kapitalmarktstorys von NanoFocus, Nanostart, Nanogate... ► Artikel lesen |